{"url_path":"/sec/jbio/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-257733-index.html","accession_number":"0001193125-26-257733","cik":"0001798749","ticker":"JBIO","issuer_name":"Jade Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-257733-index.html","primary_entity_key":"0001798749","primary_entity_name":"Jade Biosciences, Inc."},"word_count":132,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \nDescription\n\n1.1\n  \n[Underwriting Agreement, dated June 3, 2026, by and among Jade Biosciences, Inc. and Jefferies LLC, TD Securities (USA) LLC and UBS Securities LLC](d103726dex11.htm)\n\n5.1\n  \n[Opinion of Brownstein Hyatt Farber Schreck, LLP](d103726dex51.htm)\n\n23.1\n  \n[Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1)](d103726dex51.htm)\n\n99.1\n  \n[Press Release, dated June 3, 2026](d103726dex991.htm)\n\n99.2\n  \n[Press Release, dated June 3, 2026](d103726dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nJade Biosciences, Inc.\n\nDate: June 4, 2026\n \n\n \nBy:\n \n\n/s/ Bradford Dahms\n\n \n\n \nName:\n \nBradford Dahms\n\n \n\n \nTitle:\n \nChief Financial Officer and Treasurer"}